Claude generated 35,000 possible antibody shapes.
Three designs bind to immunoglobulin E; twenty can detach it from cells.
Three of the twenty performed better than existing allergy medicine.
The research is pre‑clinical, meaning it is still being studied in labs.
These antibodies aim to remove immunoglobulin E, the molecule that triggers allergic reactions.
Scientists found several designs that can bind to or pull immunoglobulin E off immune cells, some better than current drugs.
The project is still in early laboratory tests and not yet used in people.
Want to learn even more? Click here to read the full story!